 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Press ReleasesGenstruct Reaches First Performance Milestone in Multi-year Relationship with PfizerCambridge, Mass. — August 17, 2005 — Genstruct Inc., a knowledge-driven discovery company using systems biology to increase the effectiveness of drug discovery and development, today announced that it has achieved its first performance milestone in its multi-year relationship with Pfizer to help understand and treat complex diseases. The objective of this partnership is to discover critical scientific insights from large systems biology datasets in real time, and to provide causal models to answer complex therapeutic questions. “The completion of this milestone is an important achievement in our collaboration with Pfizer,” said Keith O. Elliston, Ph.D., president and CEO of Genstruct. “We have used our proprietary technology and methodology to help Pfizer’s Worldwide Safety Sciences Group investigate mechanisms of toxicity and develop biomarkers for compounds in development. We look forward to continued success in our relationship with Pfizer.” The first milestone included the development of causal system models that have been used to identify molecular mechanisms and biomarkers, and concluded with the delivery of a detailed scientific report to Pfizer that elucidates the potential mechanisms of toxicity that led to the identification of rational mechanism-based biomarkers. The multi-year agreement is the third agreement between Genstruct and Pfizer and was signed in late 2004. The details of the financial terms were not disclosed. This deal also includes research projects with Pfizer’s Discovery and Clinical Sciences units. About Genstruct Founded in 2002, Genstruct is a knowledge-driven discovery company focused on pioneering new approaches to the understanding and treatment of complex diseases in the areas of oncology, metabolic disorders and inflammation. Genstruct has developed proprietary technologies for the discovery of biomarkers, disease pathways and compound mechanisms of action (MOA). Genstruct engages in internal discovery and external development partnerships which apply systems biology to accelerate and increase the output of drug discovery and development programs. The privately held company is based in Cambridge, Mass., and its investors include Flagship Ventures and A. M. Pappas & Associates. For more information, please visit www.genstruct.com. Contact: Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com Return to Press Releases |
 |
|
 |
| One Alewife Center | Cambridge, MA 02140 | (617) 547-5421 | sitemap |